Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of nutritional indices with hyporesponsiveness to hypoxia-inducible factor-prolyl hydroxylase inhibitors in patients with chronic kidney disease: a single-center retrospective observational study.

BMC nephrology·2026
Same author

Distinct Effects of Nonselective Rho-Kinase Inhibitor Fasudil and Selective Rho-Kinase 2 Inhibitor KD025 on Serotonin and Dopamine Release in the Nucleus Accumbens of Mice.

Neuropsychopharmacology reports·2026
Same author

Phosphoproteomics identifies Rho-kinase-associated phospho-signaling and autophagy-associated alterations in the medial prefrontal cortex of a schizophrenia-related mouse model.

Pharmacological research·2026
Same author

Effectiveness of electronic patient-reported outcomes in patients with cancer undergoing immunotherapy: a real-world retrospective study.

International journal of clinical oncology·2026
Same author

Patient Education to Prevent Exposure to Anticancer Drugs among Patients and Caregivers during Outpatient Chemotherapy in Japan: A Cross-Sectional Survey.

Biological & pharmaceutical bulletin·2025
Same author

Corrigendum to "Cortical excitatory and inhibitory neuron deficits may underlie the cognitive and social impairments in a mouse model of schizophrenia with exonic Reln deletion" [Europ. J. Pharmacol. 1010 (2026) 178407].

European journal of pharmacology·2025

Related Experiment Video

Updated: May 14, 2026

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

Decrease in venous irritation by adjusting the concentration of injected bendamustine.

Hiroyuki Watanabe1, Hiroaki Ikesue, Tomoko Tsujikawa

  • 1Department of Pharmacy, Kyushu University Hospital, 3-1-1 Maidashi, Fukuoka 812-8582, Japan.

Biological & Pharmaceutical Bulletin
|February 9, 2013
PubMed
Summary

High bendamustine concentration causes venous irritation. Using 500 mL diluent significantly reduced irritation incidence in lymphoma patients, with concentrations ≤0.40 mg/mL being ideal.

More Related Videos

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Related Experiment Videos

Last Updated: May 14, 2026

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung
07:10

Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

Published on: May 20, 2019

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Pharmacy

Background:

  • Intravenous bendamustine commonly causes venous irritation, negatively impacting patient quality of life.
  • Follicular lymphoma and mantle cell lymphoma patients are susceptible to bendamustine-induced venous irritation.

Purpose of the Study:

  • To identify risk factors for bendamustine-induced venous irritation.
  • To assess the efficacy of modifying bendamustine preparation procedures to mitigate venous irritation.

Main Methods:

  • Retrospective analysis of 43 bendamustine therapy courses from electronic medical records.
  • Comparison of venous irritation incidence between bendamustine prepared with 250 mL and 500 mL diluent.
  • Evaluation of venous irritation rates before and after intervention to increase diluent volume.

Main Results:

  • Higher bendamustine concentration (0.56 mg/mL vs. 0.24 mg/mL) correlated with increased venous irritation (66% vs. 0%, p=0.01).
  • Increasing diluent volume from 250 mL to 500 mL reduced venous irritation from 58% to 20% (p=0.02).
  • Venous irritation incidence showed a concentration-dependent increase, with solutions ≤0.40 mg/mL having the lowest rates (6%).

Conclusions:

  • High bendamustine solution concentration is a significant risk factor for venous irritation.
  • Utilizing 500 mL of diluent for bendamustine preparation is recommended to minimize venous irritation.
  • Maintaining bendamustine solution concentration at or below 0.40 mg/mL is advised for optimal patient comfort and safety.